CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited

with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS,

P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of: John Joseph Deadman et al.

Application No. 10/659,179 Filed: September 9, 2003

Confirmation No. 7468

For: MULTIVALENT METAL SALTS OF

BORONIC ACIDS

Examiner: To be assigned

Art Unit: 1625

Attorney Reference No. 6613-66764

date shown below.

Date Mailed February 20, 2004

COMMISSIONER FOR PATENTS P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- X Information Disclosure Statement
 - Form PTO-1449 and references cited thereon
- \boxtimes The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- \boxtimes Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Registration No. 34,420

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc: Docketing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P38 2 4 2004

In re application of: John Joseph Deadplan et al.

Application No. 10/659,179
Filed: September 9, 2003
Confirmation No. 7468

For: MULTIVALENT METAL SALTS

BORONIC ACIDS

Examiner: To be assigned

Art Unit: 1625

Attorney Reference No. 6613-66764

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney

for Applicant(s

Date Mailed February 20, 2004

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Ry

Wayne W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

INFORMAT	ON DISCLOSURE STATEMENT
	APPLICANT

Attorney Docket Number	6613-66764	
Application Number	10/659,179	
Filing Date	September 9, 2003	
First Named Inventor	John Joseph Deadman	
Art Unit	1625	
Examiner Name	To be assigned	

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		4,499,082	12 Feb 1985	Shenvi et al.
		4,701,545	20 Oct 1987	Matteson et al.
		4,935,493	19 Jun 1990	Bachovchin et al.
		4,963,655	16 Oct 1990	Kinder et al.
		5,187,157	16 Feb 1993	Kettner et al.
		5,444,049	22 Aug 1995	de Nanteuil et al.
		5,462,964	31 Oct 1995	Fevig et al.
		5,563,127	08 Oct 1996	Amparo et al.
		5,574,014	12 Nov 1996	Claeson et al.
		5,585,360	17 Dec 1996	de Nanteuil et al.
		5,658,885	19 Aug 1997	Lee et al.
		5,681,978	28 Oct 1997	Matteson et al.
		5,731,439	24 Mar 1998	Carini et al.
		5,780,454	14 Jul 1998	Adams et al.
		5,814,622	29 Sep 1998	de Nanteuil et al.
		6,066,730	23 May 2000	Adams et al.
		6,313,096	06 Nov 2001	Claeson et al.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66764
Application Number	10/659,179
Filing Date	September 9, 2003
First Named Inventor	John Joseph Deadman
Art Unit	1625
Examiner Name	To be assigned

6,465,433 15 Oct 2002 Adams et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		0471651	19 Feb 1992	EPC
		WO 92/07869	14 May 1992	WIPO/PCT
		WO 94/21650	29 Sep 1994	WIPO/PCT
		WO 94/25049	10 Nov 1994	WIPO/PCT
		WO 95/09634	13 Apr 1995	WIPO/PCT
		WO 95/09858	13 Apr 1995	WIPO/PCT
		WO 95/09859	13 Apr 1995	WIPO/PCT
		WO 96/13266	09 May 1996	WIPO/PCT
		WO 96/20689	11 Jul 1996	WIPO/PCT
		WO 97/05161	13 Feb 1997	WIPO/PCT
		WO 98/31688	23 Jul 1998	WIPO/PCT
		WO 99/26652	03 Jun 1999	WIPO/PCT
		WO 00/35904	22 Jun 2000	WIPO/PCT
		WO 00/35905	22 Jun 2000	WIPO/PCT
		WO 00/41715	20 Jul 2000	WIPO/PCT
		WO 01/41796	14 Jun 2001	WIPO/PCT

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

					ey Docket Number	6613-66764 10/659,179
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date		September 9, 2003	
				lamed Inventor	John Joseph Deadman	
				Art Uı		1625
					ner Name	To be assigned
· · · · · · · · · · · · · · · · · · ·		WO 01/02424	11 Jan 200		WIPO/PCT	
		WO 02/36157	10 May 200	02	PCT	
<u></u>		WO 02/059130	01 Aug 200)2	WIPO/PCT	
		WO 02/059131	01 Aug 200)2	WIPO/PCT	
		WO 03/007984	30 Jan 2003	3	WIPO/PCT	
Examiner's Initials*	Cite No. (optional)		OTHER DOC	UMEN	TS	
		Claeson et al., Thror	nb Haemostas, V	Vol. 65,	p. 1289, 1991.	
		Claeson et al., "Novel peptide mimetics as highly efficient inhibitors of thrombin modified D-Phe-Pro-Arg sequences," in Peptides, Chemistry and Biology, Smith J. Rivier J E, Eds., Escom: Leiden pp. 824-825, 1992. Claeson et al., Biochem J. 290:309-312, 1993. Claeson et al., The Design of Synthetic Inhibitors of Thrombin 340:83-89, 1993. Claeson, Blood Coagulation and Fibrinolysis 5:411-436, 1994.				
					40:83-89, 1993.	
11. 11. 11. 11. 11. 11. 11. 11. 11. 11.						
		Coburn, Exp. Opin. Ther. Patents 11(5):721-738, 2001.				
	Contreras et al., J. Org. Chem. 246:213-217, 1983.					
Deadman et al., J. Medicinal Chemistry 38:1511-1522, 1995.						
🗡		Deadman et al., J. Enzyme Inhibition 9:29-41, 1995. Elgendy et al., Thromb Haemostas 65:775, 1991. Elgendy et al., Tetrahedron Letters 33(29):4209-4212, 1992.			. 17 4	
, ,	Elgendy et al., The Design of Synthetic Inhibitors of Thrombin 340:173-178, 199				340:173-178, 1993.	
		Elgendy et al., Tetra	hedron 50(12):3	803-38	12, 1994.	
EXAMINER SIGNATUR		t e trou e tagé de la companya de determinante de la companya de de la companya d	1	DATE CONSID	ERED:	
		reference considered, w				Draw line through cite if not applicant.

		Attorney Docket Number	6613-66764
		Application Number	10/659,179
INFORMATION DISCLOSURE STATEMENT		Filing Date	September 9, 2003
BY A	BY APPLICANT		John Joseph Deadman
		Art Unit	1625
		Examiner Name	To be assigned
Es	mail et al., Thrombosis and Haeme	ostasis 6:1318, 1995.	
Ea	mail at al. Thuambasis and Hassa	antonia 5:01 02 1007	
LS	smail et al., <i>Thrombosis and Haem</i>	USIUSIS 3.91-92, 1997.	
Es	mail et al., Thrombosis and Haemo	ostasis 5:498-499, 1997.	
Ge	errard et al., Thrombosis and Haem	nostasis 6:1307, 1995.	
Gu	ustafsson et al., Thrombosis Resear	rch 101:171-181, 2001.	
Ka	atz et al., Biochemistry 34(26):8264	4-8280, 1995.	
M	Martichonok et al., J. Am. Chem. Soc. 118:950-958, 1996.		
M	att et al., Bioorg. Med. Chem. 8:22	91-2303, 2000.	
. M	atteson, Chem. Rev. 89:1535-1551	, 1989.	
M	atteson et al., J. Org. Chem. 61:60-	47-6051, 1996.	// // // // // // // // // // // // //
M	etternich et al., Naunyn-Schmiedeb	oerg's Arch Pharmocol 97:3	45, 1992.
Ph	nilipp et al., The Design of Syntheti	c Inhibitors of Thrombin 34	0:67-77, 1993.
Re	ewinkel et al., Current Pharmaceur	tical Design 5:1043-1075, 1	999.
Sa	itoh et al., <i>Pharmaceutical Resear</i>	ch 16(11):1786-1789, 1999	
Sa	nderson et al., Current Medicinal	Chemistry 5:289-304, 1998.	
Sk	cordalakes et al., Biochemistry 37(4	11):14420-14427, 1998.	
Sp	pencer et al., Tetrahedron 58:1551-	1556, 2002.	
1 1	ahl et al., <i>Handbook of Pharmaceu</i> elvetica Chimica Acta, Postfach, C	•	
	pparelli et al., "The Journal of Bio		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	6613-66764
INFORMATION DISCLOSURE STATEMENT		Application Number	10/659,179
		Filing Date	September 9, 2003
	BY APPLICANT	First Named Inventor	John Joseph Deadman
		Art Unit	1625
		Examiner Name	To be assigned
	Tapparelli et al., Trends Pharmacol.	Sci. 14:366-376, 1993.	
	Trigen Limited, TRI 50b Non Confid	lential Information pp. 1-12,	July 2002.
	Trigen Limited, "Looking for a caree International Symposium on Medicin	nal Chemistry, Barcelona, S	
	Tripathy et al., Synthesis pp. 200-200	5, 1990.	
	Wu et al., Journal of Pharmaceutica	l Sciences 89(6):758-765, Ju	ine 2000.
	Yang et al., Pharmaceutical Research	h 16(9):1331-1343, 1999.	
	Yang et al., Medicinal Research Reviews 23(3):346-368, 2003.		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATORE,	CONSIDERED.

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.